Abacus Bioscience
WA - SeattleBiotechnology
Focus: Abacus Bioscience is an early-stage biotechnology company founded in 2023, focused on developing anti-CD180 monoclonal antibodies across multiple therapeutic areas including gastroenterology, ophthalmology, neurology, dermatology, and infectious diseases.
Profile data last refreshed 2h ago · AI intelligence enriched 2w ago
Open Jobs
69+29 this month
Hot — 57 jobs added in 30d
Net +29 (57 new, 28 removed). Aggressive expansion phase.
Should You Work at Abacus Bioscience?
AI assessmentAbacus is a high-upside, high-risk pre-revenue play suitable for scientists seeking platform ownership and commercial acceleration, but unsuitable for those prioritizing near-term data readouts or financial transparency.
Why Work Here
- Ground-floor opportunity at a newly founded biotech (2023) with a differentiated mechanism (anti-CD180 mAbs) spanning five disease areas, offering early-career scientists and clinicians significant influence on platform direction.
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
0 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Abacus Bioscience
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.